# A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

> **NCT01804140** · — · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 662 (actual)

## Conditions studied

- Multiple Myeloma, Neoplasms

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01804140
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 662 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01804140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01804140, "A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01804140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*